Remimazolam vs. dexmedetomidine for postoperative sedation in patients with Stanford type A aortic dissection: a randomized controlled trial

Introduction Multi-organ dysfunction can occur in patients following acute Stanford type A aortic dissection (AAAD) surgery. We aimed to evaluate the use of remimazolam versus dexmedetomidine for sedation in postoperative AAAD patients. Methods This single-center, prospective, double-blind, randomized controlled trial was conducted between July 2021 and July 2023. Patients undergoing AAAD repair were randomly assigned to receive either remimazolam or dexmedetomidine, and the patients’ sedation level was then evaluated utilizing the Richmond Agitation and Sedation Scale (RASS). The primary study outcome was the percentage of duration during which the patients maintained a targeted RASS score between −3 and 0. The secondary study outcomes included an exploratory analysis of the percentage of the total intervention duration during which the patients maintained a targeted optimal RASS score between −2 and 0, the mechanical ventilation and sedation durations, pain intensity, length of stay in the intensive care unit and hospital stay, Acute Physiologic Assessment and Chronic Health Evaluation II score, and laboratory test results. Results In total, 524 patients were included in the study, with 262 patients in each of the remimazolam and dexmedetomidine groups, and these were all included in the intention-to-treat analysis. The patients’ baseline characteristics and sedative infusion durations were similar between the two groups ( p > 0.05). The time-weighted percentages within the target RASS range of −3–0 were 85.7% (interquartile range 77.8–94.7) and 81.7% (interquartile range 70.0–91.7) in the remimazolam and dexmedetomidine groups, respectively, with a median inter-group difference of 4.0% (95% confidence interval: 0.0–8.5; p = 0.016), while the percentage duration in the optimal RASS range was higher in the remimazolam group than in the dexmedetomidine group (87.5% vs. 85.1%, p = 0.009). Otherwise, the two groups showed comparable results for the other secondary outcomes and adverse events. Conclusions Remimazolam could provide safe and better overall postoperative sedation than dexmedetomidine in patients undergoing AAAD surgery. Clinical Trial Registration Chinese Clinical Trial Registry (chictr.gov, registration number: ChiCTR2100048540).

Authors

Institutions

Publication Details

Journal
Frontiers in Cardiovascular Medicine
Published
2026-11-18
DOI
https://doi.org/10.3389/fcvm.2026.1980137
Primary Topic
Anesthesia and Sedative Agents
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Remimazolam vs. dexmedetomidine for postoperative sedation in patients with Stanford type A aortic dissection: a randomized controlled trial

Ya Li, Faming He, Shumin Wu, 史博伦 et al.
2 links
Frontiers in Cardiovascular Medicine
Anesthesia and Sedative Agents
article

Remimazolam vs. dexmedetomidine for postoperative sedation in patients with Stanford type A aortic dissection: a randomized controlled trial

Ya Li, Faming He, Shumin Wu, 史博伦, Feng Zhang, Yangtao Yu, Zhe Ding, Hui Wang, Xiangbo Cao, Jingkun Zhu
article en

Abstract

Introduction Multi-organ dysfunction can occur in patients following acute Stanford type A aortic dissection (AAAD) surgery. We aimed to evaluate the use of remimazolam versus dexmedetomidine for sedation in postoperative AAAD patients. Methods This single-center, prospective, double-blind, randomized controlled trial was conducted between July 2021 and July 2023. Patients undergoing AAAD repair were randomly assigned to receive either remimazolam or dexmedetomidine, and the patients’ sedation level was then evaluated utilizing the Richmond Agitation and Sedation Scale (RASS). The primary study outcome was the percentage of duration during which the patients maintained a targeted RASS score between −3 and 0. The secondary study outcomes included an exploratory analysis of the percentage of the total intervention duration during which the patients maintained a targeted optimal RASS score between −2 and 0, the mechanical ventilation and sedation durations, pain intensity, length of stay in the intensive care unit and hospital stay, Acute Physiologic Assessment and Chronic Health Evaluation II score, and laboratory test results. Results In total, 524 patients were included in the study, with 262 patients in each of the remimazolam and dexmedetomidine groups, and these were all included in the intention-to-treat analysis. The patients’ baseline characteristics and sedative infusion durations were similar between the two groups ( p > 0.05). The time-weighted percentages within the target RASS range of −3–0 were 85.7% (interquartile range 77.8–94.7) and 81.7% (interquartile range 70.0–91.7) in the remimazolam and dexmedetomidine groups, respectively, with a median inter-group difference of 4.0% (95% confidence interval: 0.0–8.5; p = 0.016), while the percentage duration in the optimal RASS range was higher in the remimazolam group than in the dexmedetomidine group (87.5% vs. 85.1%, p = 0.009). Otherwise, the two groups showed comparable results for the other secondary outcomes and adverse events. Conclusions Remimazolam could provide safe and better overall postoperative sedation than dexmedetomidine in patients undergoing AAAD surgery. Clinical Trial Registration Chinese Clinical Trial Registry (chictr.gov, registration number: ChiCTR2100048540).

Frontiers in Cardiovascular MedicineVol. 13
Henan Provincial Chest Hospital (CN)
Good health and well-being
Anesthesia and Sedative Agents
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon